Fergus Hamilton

Dr. Fergus Hamilton is a NIHR Clinical Lecturer at the Bristol Medical School (PHS), University of Bristol. His research focuses on infectious diseases, critical care medicine, and clinical trials, particularly in the context of antibiotic resistance and sepsis management. He has contributed to high-impact studies on Mendelian randomization techniques, cytokine signaling pathways (e.g., IL-6), and the efficacy of antiviral and corticosteroid therapies in severe infections like COVID-19. His work often involves large-scale clinical trials (e.g., the RECOVERY trial series) and collaborations across disciplines to address pressing challenges in infectious disease treatment and public health policy.

Education: Holds a PhD, though specific details are not listed. Research interests include antibiotic prescribing trends, diagnostic delays in blood cultures, and the genetic determinants of infection outcomes. He has published extensively on topics such as pleural infections, sepsis biomarkers, and the impact of influenza vaccination on cardiovascular events.

His recent publications highlight methodological advancements in Mendelian randomization and clinical guidelines for urinary tract infections. He actively engages in interdisciplinary research, collaborating with experts in genetics, immunology, and clinical pharmacology.

Advising and grants: No formal advisees or grant details are listed, though his involvement in major trials suggests active participation in collaborative research funding.

Labs/teams: Collaborates with prominent researchers such as Professors Jonathan Reid (School of Chemistry), Nicholas Timpson (Genetic Epidemiology), and Nick Maskell (Respiratory Medicine) at the University of Bristol.